Parkinson's disease

The Lancet - Tập 386 - Trang 896-912 - 2015
Lorraine V Kalia1, Anthony E Lang1
1Morton and Gloria Shulman Movement Disorders Clinic and the Edmond J Safra Program in Parkinson's Disease, Toronto Western Hospital, Division of Neurology, Department of Medicine, University of Toronto, Toronto, ON, Canada

Tài liệu tham khảo

Goetz, 2011, The history of Parkinson's disease: early clinical descriptions and neurological therapies, Cold Spring Harb Perspect Med, 1, a008862, 10.1101/cshperspect.a008862 Gibb, 1988, The relevance of the Lewy body to the pathogenesis of idiopathic Parkinson's disease, J Neurol Neurosurg Psychiatry, 51, 745, 10.1136/jnnp.51.6.745 Marras, 2013, Parkinson's disease subtypes: lost in translation?, J Neurol Neurosurg Psychiatry, 84, 409, 10.1136/jnnp-2012-303455 Jankovic, 1990, Variable expression of Parkinson's disease: a base-line analysis of the DATATOP cohort. The Parkinson Study Group, Neurology, 40, 1529, 10.1212/WNL.40.10.1529 Khoo, 2013, The spectrum of nonmotor symptoms in early Parkinson disease, Neurology, 80, 276, 10.1212/WNL.0b013e31827deb74 Martinez-Martin, 2011, The impact of non-motor symptoms on health-related quality of life of patients with Parkinson's disease, Mov Disord, 26, 399, 10.1002/mds.23462 Duncan, 2014, Health-related quality of life in early Parkinson's disease: the impact of nonmotor symptoms, Mov Disord, 29, 195, 10.1002/mds.25664 Postuma, 2012, Identifying prodromal Parkinson's disease: pre-motor disorders in Parkinson's disease, Mov Disord, 27, 617, 10.1002/mds.24996 2005 Aurora, 2010, Best practice guide for the treatment of REM sleep behavior disorder (RBD), J Clin Sleep Med, 6, 85, 10.5664/jcsm.27717 Postuma, 2009, Quantifying the risk of neurodegenerative disease in idiopathic REM sleep behavior disorder, Neurology, 72, 1296, 10.1212/01.wnl.0000340980.19702.6e Schenck, 2013, Delayed emergence of a parkinsonian disorder or dementia in 81% of older men initially diagnosed with idiopathic rapid eye movement sleep behavior disorder: a 16-year update on a previously reported series, Sleep Med, 14, 744, 10.1016/j.sleep.2012.10.009 Iranzo, 2013, Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study, Lancet Neurol, 12, 443, 10.1016/S1474-4422(13)70056-5 Noyce, 2012, Meta-analysis of early nonmotor features and risk factors for Parkinson disease, Ann Neurol, 72, 893, 10.1002/ana.23687 Siderowf, 2012, Premotor Parkinson's disease: concepts and definitions, Mov Disord, 27, 608, 10.1002/mds.24954 Hely, 2005, Sydney multicenter study of Parkinson's disease: non-L-dopa-responsive problems dominate at 15 years, Mov Disord, 20, 190, 10.1002/mds.20324 Hely, 2008, The Sydney multicenter study of Parkinson's disease: the inevitability of dementia at 20 years, Mov Disord, 23, 837, 10.1002/mds.21956 Coelho, 2012, Late-stage Parkinson disease, Nat Rev Neurol, 8, 435, 10.1038/nrneurol.2012.126 Dorsey, 2007, Projected number of people with Parkinson disease in the most populous nations, 2005 through 2030, Neurology, 68, 384, 10.1212/01.wnl.0000247740.47667.03 2014, 2014 Alzheimer's disease facts and figures, Alzheimers Dement, 10, e47 Von Campenhausen, 2005, Prevalence and incidence of Parkinson's disease in Europe, Eur Neuropsychopharmacol, 15, 473, 10.1016/j.euroneuro.2005.04.007 Strickland, 2004, Parkinson's prevalence estimated by a state registry, Mov Disord, 19, 318, 10.1002/mds.10619 Bauso, 2012, Incidence and prevalence of Parkinson's disease in Buenos Aires City, Argentina, Eur J Neurol, 19, 1108, 10.1111/j.1468-1331.2012.03683.x Okubadejo, 2006, Parkinson's disease in Africa: a systematic review of epidemiologic and genetic studies, Mov Disord, 21, 2150, 10.1002/mds.21153 Muangpaisan, 2009, Systematic review of the prevalence and incidence of Parkinson's disease in Asia, J Epidemiol, 19, 281, 10.2188/jea.JE20081034 Benamer, 2008, Parkinson's disease in Arabs: a systematic review, Mov Disord, 23, 1205, 10.1002/mds.22041 Van Den Eeden, 2003, Incidence of Parkinson's disease: variation by age, gender, and race/ethnicity, Am J Epidemiol, 157, 1015, 10.1093/aje/kwg068 De Lau, 2006, Epidemiology of Parkinson's disease, Lancet Neurol, 5, 525, 10.1016/S1474-4422(06)70471-9 Driver, 2009, Incidence and remaining lifetime risk of Parkinson disease in advanced age, Neurology, 72, 432, 10.1212/01.wnl.0000341769.50075.bb Pringsheim, 2014, The prevalence of Parkinson's disease: a systematic review and meta-analysis, Mov Disord, 29, 1583, 10.1002/mds.25945 Ritz, 2014, Parkinson disease and smoking revisited: ease of quitting is an early sign of the disease, Neurology, 83, 1396, 10.1212/WNL.0000000000000879 Cipriani, 2010, Urate: a novel biomarker of Parkinson's disease risk, diagnosis and prognosis, Biomark Med, 4, 701, 10.2217/bmm.10.94 Mortimer, 2012, Associations of welding and manganese exposure with Parkinson disease: review and meta-analysis, Neurology, 79, 1174, 10.1212/WNL.0b013e3182698ced Foubert-Samier, 2012, Past exposure to neuroleptic drugs and risk of Parkinson disease in an elderly cohort, Neurology, 79, 1615, 10.1212/WNL.0b013e31826e25ce Goldman, 2012, Solvent exposures and Parkinson disease risk in twins, Ann Neurol, 71, 776, 10.1002/ana.22629 Polymeropoulos, 1997, Mutation in the alpha-synuclein gene identified in families with Parkinson's disease, Science, 276, 2045, 10.1126/science.276.5321.2045 Corti, 2011, What genetics tells us about the causes and mechanisms of Parkinson's disease, Physiol Rev, 91, 1161, 10.1152/physrev.00022.2010 Sidransky, 2012, The link between the GBA gene and parkinsonism, Lancet Neurol, 11, 986, 10.1016/S1474-4422(12)70190-4 Sidransky, 2009, Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease, N Engl J Med, 361, 1651, 10.1056/NEJMoa0901281 Nalls, 2014, Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease, Nat Genet, 46, 989, 10.1038/ng.3043 Lee, 2012, Traumatic brain injury, paraquat exposure, and their relationship to Parkinson disease, Neurology, 79, 2061, 10.1212/WNL.0b013e3182749f28 Popat, 2011, Coffee, ADORA2A, and CYP1A2: the caffeine connection in Parkinson's disease, Eur J Neurol, 18, 756, 10.1111/j.1468-1331.2011.03353.x Hamza, 2011, Genome-wide gene-environment study identifies glutamate receptor gene GRIN2A as a Parkinson's disease modifier gene via interaction with coffee, Plos Genet, 7, e1002237, 10.1371/journal.pgen.1002237 Goldman, 2012, Head injury, alpha-synuclein Rep1, and Parkinson's disease, Ann Neurol, 71, 40, 10.1002/ana.22499 Dickson, 2009, Neuropathological assessment of Parkinson's disease: refining the diagnostic criteria, Lancet Neurol, 8, 1150, 10.1016/S1474-4422(09)70238-8 Kordower, 2013, Disease duration and the integrity of the nigrostriatal system in Parkinson's disease, Brain, 136, 2419, 10.1093/brain/awt192 Dickson, 2012, Parkinson's disease and parkinsonism: neuropathology, Cold Spring Harb Perspect Med, 2, a009258, 10.1101/cshperspect.a009258 Masters, 2011, Overview and recent advances in neuropathology. Part 2: Neurodegeneration, Pathology, 43, 93, 10.1097/PAT.0b013e3283426eee Spillantini, 1997, Alpha-synuclein in Lewy bodies, Nature, 388, 839, 10.1038/42166 Goedert, 2012, 100 years of Lewy pathology, Nat Rev Neurol, 9, 13, 10.1038/nrneurol.2012.242 Iwanaga, 1999, Lewy body-type degeneration in cardiac plexus in Parkinson's and incidental Lewy body diseases, Neurology, 52, 1269, 10.1212/WNL.52.6.1269 Fumimura, 2007, Analysis of the adrenal gland is useful for evaluating pathology of the peripheral autonomic nervous system in lewy body disease, J Neuropathol Exp Neurol, 66, 354, 10.1097/nen.0b013e3180517454 Beach, 2010, Multi-organ distribution of phosphorylated alpha-synuclein histopathology in subjects with Lewy body disorders, Acta Neuropathol, 119, 689, 10.1007/s00401-010-0664-3 Del Tredici, 2010, Lewy pathology in the submandibular gland of individuals with incidental Lewy body disease and sporadic Parkinson's disease, Acta Neuropathol, 119, 703, 10.1007/s00401-010-0665-2 Braak, 2003, Staging of brain pathology related to sporadic Parkinson's disease, Neurobiol Aging, 24, 197, 10.1016/S0197-4580(02)00065-9 Selikhova, 2009, A clinico-pathological study of subtypes in Parkinson's disease, Brain, 132, 2947, 10.1093/brain/awp234 Kempster, 2010, Relationships between age and late progression of Parkinson's disease: a clinico-pathological study, Brain, 133, 1755, 10.1093/brain/awq059 Irwin, 2012, Neuropathologic substrates of Parkinson disease dementia, Ann Neurol, 72, 587, 10.1002/ana.23659 Parkkinen, 2008, Applicability of current staging/categorization of alpha-synuclein pathology and their clinical relevance, Acta Neuropathol, 115, 399, 10.1007/s00401-008-0346-6 Halliday, 2008, The progression of pathology in longitudinally followed patients with Parkinson's disease, Acta Neuropathol, 115, 409, 10.1007/s00401-008-0344-8 Saito, 2003, Accumulation of phosphorylated alpha-synuclein in aging human brain, J Neuropathol Exp Neurol, 62, 644, 10.1093/jnen/62.6.644 Kovacs, 2012, An antibody with high reactivity for disease-associated α-synuclein reveals extensive brain pathology, Acta Neuropathol, 124, 37, 10.1007/s00401-012-0964-x Schulz-Schaeffer, 2010, The synaptic pathology of α-synuclein aggregation in dementia with Lewy bodies, Parkinson's disease and Parkinson's disease dementia, Acta Neuropathol, 120, 131, 10.1007/s00401-010-0711-0 Cremades, 2012, Direct observation of the interconversion of normal and toxic forms of α-synuclein, Cell, 149, 1048, 10.1016/j.cell.2012.03.037 Kalia, 2013, α-Synuclein oligomers and clinical implications for Parkinson disease, Ann Neurol, 73, 155, 10.1002/ana.23746 Compta, 2011, Lewy- and Alzheimer-type pathologies in Parkinson's disease dementia: which is more important?, Brain, 134, 1493, 10.1093/brain/awr031 Irwin, 2013, Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies, Nat Rev Neurosci, 14, 626, 10.1038/nrn3549 Doherty, 2013, Parkin disease: a clinicopathologic entity?, JAMA Neurol, 70, 571, 10.1001/jamaneurol.2013.172 Poulopoulos, 2012, The neuropathology of genetic Parkinson's disease, Mov Disord, 27, 831, 10.1002/mds.24962 Kalia, 2015, Clinical correlations with Lewy body pathology in LRRK2-related Parkinson's disease, JAMA Neurol, 72, 100, 10.1001/jamaneurol.2014.2704 Tansey, 2010, Neuroinflammation in Parkinson's disease: its role in neuronal death and implications for therapeutic intervention, Neurobiol Dis, 37, 510, 10.1016/j.nbd.2009.11.004 Phani, 2012, Neurodegeneration and inflammation in Parkinson's disease, Parkinsonism Relat Disord, 18, S207, 10.1016/S1353-8020(11)70064-5 Devine, 2011, Parkinson's disease and alpha-synuclein expression, Mov Disord, 26, 2160, 10.1002/mds.23948 Cookson, 2012, Cellular effects of LRRK2 mutations, Biochem Soc Trans, 40, 1070, 10.1042/BST20120165 Dzamko, 2012, An emerging role for LRRK2 in the immune system, Biochem Soc Trans, 40, 1134, 10.1042/BST20120119 Lee, 2012, The synaptic function of LRRK2, Biochem Soc Trans, 40, 1047, 10.1042/BST20120113 Sanna, 2012, LRRK2 and vesicle trafficking, Biochem Soc Trans, 40, 1117, 10.1042/BST20120117 Martin, 2014, Ribosomal protein s15 phosphorylation mediates LRRK2 neurodegeneration in Parkinson's disease, Cell, 157, 472, 10.1016/j.cell.2014.01.064 Paisán-Ruíz, 2004, Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease, Neuron, 44, 595, 10.1016/j.neuron.2004.10.023 Healy, 2008, Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study, Lancet Neurol, 7, 583, 10.1016/S1474-4422(08)70117-0 Aasly, 2010, Novel pathogenic LRRK2 p.Asn1437His substitution in familial Parkinson's disease, Mov Disord, 25, 2156, 10.1002/mds.23265 Ozelius, 2006, LRRK2 G2019S as a cause of Parkinson's disease in Ashkenazi Jews, N Engl J Med, 354, 424, 10.1056/NEJMc055509 Lesage, 2006, LRRK2 G2019S as a cause of Parkinson's disease in North African Arabs, N Engl J Med, 354, 422, 10.1056/NEJMc055540 Zimprich, 2011, A mutation in VPS35, encoding a subunit of the retromer complex, causes late-onset Parkinson disease, Am J Hum Genet, 89, 168, 10.1016/j.ajhg.2011.06.008 Vilariño-Güell, 2011, VPS35 mutations in Parkinson disease, Am J Hum Genet, 89, 162, 10.1016/j.ajhg.2011.06.001 Chartier-Harlin, 2011, Translation initiator EIF4G1 mutations in familial Parkinson disease, Am J Hum Genet, 89, 398, 10.1016/j.ajhg.2011.08.009 Vilariño-Güell, 2014, DNAJC13 mutations in Parkinson disease, Hum Mol Genet, 23, 1794, 10.1093/hmg/ddt570 Funayama, 2015, CHCHD2 mutations in autosomal dominant late-onset Parkinson's disease: a genome-wide linkage and sequencing study, Lancet Neurol, 14, 274, 10.1016/S1474-4422(14)70266-2 Bonifacino, 2008, Retromer, Curr Opin Cell Biol, 20, 427, 10.1016/j.ceb.2008.03.009 Tucci, 2012, Study of the genetic variability in a Parkinson's Disease gene: EIF4G1, Neurosci Lett, 518, 19, 10.1016/j.neulet.2012.04.033 Schulte, 2012, Variants in eukaryotic translation initiation factor 4G1 in sporadic Parkinson's disease, Neurogenetics, 13, 281, 10.1007/s10048-012-0334-9 Schrag, 2006, Epidemiological, clinical, and genetic characteristics of early-onset parkinsonism, Lancet Neurol, 5, 355, 10.1016/S1474-4422(06)70411-2 Lücking, 2000, Association between early-onset Parkinson's disease and mutations in the parkin gene, N Engl J Med, 342, 1560, 10.1056/NEJM200005253422103 Periquet, 2003, Parkin mutations are frequent in patients with isolated early-onset parkinsonism, Brain, 126, 1271, 10.1093/brain/awg136 Singleton, 2013, The genetics of Parkinson's disease: progress and therapeutic implications, Mov Disord, 28, 14, 10.1002/mds.25249 Klein, 2007, Deciphering the role of heterozygous mutations in genes associated with parkinsonism, Lancet Neurol, 6, 652, 10.1016/S1474-4422(07)70174-6 Mccoy, 2012, Mitochondrial quality control and dynamics in Parkinson's disease, Antioxid Redox Signal, 16, 869, 10.1089/ars.2011.4019 Puschmann, 2013, Monogenic Parkinson's disease and parkinsonism: clinical phenotypes and frequencies of known mutations, Parkinsonism Relat Disord, 19, 407, 10.1016/j.parkreldis.2013.01.020 Krebs, 2013, The Sac1 domain of SYNJ1 identified mutated in a family with early-onset progressive parkinsonism with generalized seizures, Hum Mutat, 34, 1200, 10.1002/humu.22372 Quadri, 2013, Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset parkinsonism, Hum Mutat, 34, 1208, 10.1002/humu.22373 Wilson, 2014, Mutations in RAB39B cause X-linked intellectual disability and early-onset Parkinson disease with α-synuclein pathology, Am J Hum Genet, 95, 729, 10.1016/j.ajhg.2014.10.015 Butcher, 2013, Association between early-onset Parkinson disease and 22q11.2 deletion syndrome: identification of a novel genetic form of Parkinson disease and its clinical implications, JAMA Neurol, 70, 1359, 10.1001/jamaneurol.2013.3646 Trinh, 2013, Advances in the genetics of Parkinson disease, Nat Rev Neurol, 9, 445, 10.1038/nrneurol.2013.132 Bezard, 2011, A tale on animal models of Parkinson's disease, Mov Disord, 26, 993, 10.1002/mds.23696 Hawkes, 2007, Parkinson's disease: a dual-hit hypothesis, Neuropathol Appl Neurobiol, 33, 599, 10.1111/j.1365-2990.2007.00874.x Kordower, 2008, Lewy body-like pathology in long-term embryonic nigral transplants in Parkinson's disease, Nat Med, 14, 504, 10.1038/nm1747 Kordower, 2008, Transplanted dopaminergic neurons develop PD pathologic changes: a second case report, Mov Disord, 23, 2303, 10.1002/mds.22369 Li, 2008, Lewy bodies in grafted neurons in subjects with Parkinson's disease suggest host-to-graft disease propagation, Nat Med, 14, 501, 10.1038/nm1746 Visanji, 2013, The prion hypothesis in Parkinson's disease: Braak to the future, Acta Neuropathol Commun, 1, 2, 10.1186/2051-5960-1-2 Luk, 2012, Intracerebral inoculation of pathological alpha-synuclein initiates a rapidly progressive neurodegenerative alpha-synucleinopathy in mice, J Exp Med, 209, 975, 10.1084/jem.20112457 Luk, 2012, Pathological alpha-synuclein transmission initiates Parkinson-like neurodegeneration in nontransgenic mice, Science, 338, 949, 10.1126/science.1227157 Masuda-Suzukake, 2013, Prion-like spreading of pathological α-synuclein in brain, Brain, 136, 1128, 10.1093/brain/awt037 Sacino, 2013, Induction of CNS alpha-synuclein pathology by fibrillar and non-amyloidogenic recombinant alpha-synuclein, Acta Neuropathol Commun, 1, 38, 10.1186/2051-5960-1-38 Recasens, 2014, Lewy body extracts from Parkinson disease brains trigger α-synuclein pathology and neurodegeneration in mice and monkeys, Ann Neurol, 75, 351, 10.1002/ana.24066 Surmeier, 2012, Calcium, bioenergetics, and neuronal vulnerability in Parkinson's disease, J Biol Chem, 288, 10736, 10.1074/jbc.R112.410530 Chen, 2012, Urate in Parkinson's disease: more than a biomarker?, Curr Neurol Neurosci Rep, 12, 367, 10.1007/s11910-012-0282-7 Greenamyre, 2004, Biomedicine. Parkinson's—divergent causes, convergent mechanisms, Science, 304, 1120, 10.1126/science.1098966 Sian-Hülsmann, 2011, The relevance of iron in the pathogenesis of Parkinson's disease, J Neurochem, 118, 939, 10.1111/j.1471-4159.2010.07132.x Hughes, 2001, Improved accuracy of clinical diagnosis of Lewy body Parkinson's disease, Neurology, 57, 1497, 10.1212/WNL.57.8.1497 Gelb, 1999, Diagnostic criteria for Parkinson disease, Arch Neurol, 56, 33, 10.1001/archneur.56.1.33 Berg, 2013, Changing the research criteria for the diagnosis of Parkinson's disease: obstacles and opportunities, Lancet Neurol, 12, 514, 10.1016/S1474-4422(13)70047-4 Berg, 2014, Time to redefine PD? Introductory statement of the MDS Task Force on the definition of Parkinson's disease, Mov Disord, 29, 454, 10.1002/mds.25844 2000, Pramipexole vs levodopa as initial treatment for Parkinson disease: a randomized controlled trial. Parkinson Study Group, JAMA, 284, 1931, 10.1001/jama.284.15.1931 Fahn, 2004, Levodopa and the progression of Parkinson's disease, N Engl J Med, 351, 2498, 10.1056/NEJMoa033447 2007, Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease, Neurology, 69, 1480, 10.1212/01.wnl.0000277648.63931.c0 Whone, 2003, Slower progression of Parkinson's disease with ropinirole versus levodopa: The REAL-PET study, Ann Neurol, 54, 93, 10.1002/ana.10609 Brooks, 2011, Imaging biomarkers in Parkinson's disease, Prog Neurobiol, 95, 614, 10.1016/j.pneurobio.2011.08.009 Marek, 2014, Longitudinal follow-up of SWEDD subjects in the PRECEPT Study, Neurology, 82, 1791, 10.1212/WNL.0000000000000424 Kraemmer, 2014, Correlation of striatal dopamine transporter imaging with post mortem substantia nigra cell counts, Mov Disord, 29, 1767, 10.1002/mds.25975 Salsone, 2012, Cardiac denervation precedes nigrostriatal damage in idiopathic rapid eye movement sleep behavior disorder, Mov Disord, 27, 1068, 10.1002/mds.25002 Iranzo, 2014, Neuropathology of prodromal Lewy body disease, Mov Disord, 29, 410, 10.1002/mds.25825 Lehéricy, 2012, Magnetic resonance imaging of the substantia nigra in Parkinson's disease, Mov Disord, 27, 822, 10.1002/mds.25015 Cochrane, 2013, Diffusion tensor imaging in parkinsonian syndromes: a systematic review and meta-analysis, Neurology, 80, 857, 10.1212/WNL.0b013e318284070c Lehéricy, 2014, 7 tesla magnetic resonance imaging: a closer look at substantia nigra anatomy in Parkinson's disease, Mov Disord, 29, 1574, 10.1002/mds.26043 Visanji, 2014, Alimentary, my dear Watson? The challenges of enteric α-synuclein as a Parkinson's disease biomarker, Mov Disord, 29, 444, 10.1002/mds.25789 Shannon, 2012, Is alpha-synuclein in the colon a biomarker for premotor Parkinson's disease? Evidence from 3 cases, Mov Disord, 27, 716, 10.1002/mds.25020 Böttner, 2012, Expression pattern and localization of alpha-synuclein in the human enteric nervous system, Neurobiol Dis, 48, 474, 10.1016/j.nbd.2012.07.018 Gold, 2013, Enteric alpha-synuclein expression is increased in Parkinson's disease but not Alzheimer's disease, Mov Disord, 28, 237, 10.1002/mds.25298 Visanji, 2015, Colonic mucosal α-synuclein lacks specificity as a biomarker for Parkinson disease, Neurology, 84, 609, 10.1212/WNL.0000000000001240 Donadio, 2014, Skin nerve α-synuclein deposits: a biomarker for idiopathic Parkinson disease, Neurology, 82, 1362, 10.1212/WNL.0000000000000316 Hong, 2010, DJ-1 and α-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease, Brain, 133, 713, 10.1093/brain/awq008 Parnetti, 2013, Cerebrospinal fluid biomarkers in Parkinson disease, Nat Rev Neurol, 9, 131, 10.1038/nrneurol.2013.10 Eller, 2009, Biological fluid biomarkers in neurodegenerative parkinsonism, Nat Rev Neurol, 5, 561, 10.1038/nrneurol.2009.135 Stewart, 2014, Cheek cell–derived α-synuclein and DJ-1 do not differentiate Parkinson's disease from control, Neurobiol Aging, 35, 418, 10.1016/j.neurobiolaging.2013.08.008 Bogdanov, 2008, Metabolomic profiling to develop blood biomarkers for Parkinson's disease, Brain, 131, 389, 10.1093/brain/awm304 Shi, 2011, Cerebrospinal fluid biomarkers for Parkinson disease diagnosis and progression, Ann Neurol, 69, 570, 10.1002/ana.22311 Aldakheel, 2014, Pathogenesis-targeted, disease-modifying therapies in Parkinson disease, Neurother, 11, 6, 10.1007/s13311-013-0218-1 Tran, 2014, α-Synuclein immunotherapy blocks uptake and templated propagation of misfolded α-synuclein and neurodegeneration, Cell Rep, 7, 2054, 10.1016/j.celrep.2014.05.033 Coune, 2012, Parkinson's disease: gene therapies, Cold Spring Harb Perspect Med, 2, a009431, 10.1101/cshperspect.a009431 Kordower, 2013, Trophic factor gene therapy for Parkinson's disease, Mov Disord, 28, 96, 10.1002/mds.25344 Bjorklund, 2013, Cell therapy for Parkinson's disease: what next?, Mov Disord, 28, 110, 10.1002/mds.25343 Lindvall, 2013, Developing dopaminergic cell therapy for Parkinson's disease—give up or move forward?, Mov Disord, 28, 268, 10.1002/mds.25378 Charles, 2014, Subthalamic nucleus deep brain stimulation in early stage Parkinson's disease, Parkinsonism Relat Disord, 20, 731, 10.1016/j.parkreldis.2014.03.019 Fox, 2011, The Movement Disorder Society evidence-based medicine review update: treatments for the motor symptoms of Parkinson's disease, Mov Disord, 26, S2, 10.1002/mds.23829 Connolly, 2014, Pharmacological treatment of Parkinson's disease: a review, JAMA, 311, 1670, 10.1001/jama.2014.3654 2014, Long-term effectiveness of dopamine agonists and monoamine oxidase B inhibitors compared with levodopa as initial treatment for Parkinson's disease (PD MED): a large, open-label, pragmatic randomised trial, Lancet, 384, 1196, 10.1016/S0140-6736(14)60683-8 Lang, 2014, Initiating dopaminergic treatment in Parkinson's disease, Lancet, 384, 1164, 10.1016/S0140-6736(14)60962-4 Hauser, 2013, Extended-release carbidopa-levodopa (IPX066) compared with immediate-release carbidopa-levodopa in patients with Parkinson's disease and motor fluctuations: a phase 3 randomised, double-blind trial, Lancet Neurol, 12, 346, 10.1016/S1474-4422(13)70025-5 Olanow, 2014, Continuous intrajejunal infusion of levodopa-carbidopa intestinal gel for patients with advanced Parkinson's disease: a randomised, controlled, double-blind, double-dummy study, Lancet Neurol, 13, 141, 10.1016/S1474-4422(13)70293-X Kalia, 2013, Novel nondopaminergic targets for motor features of Parkinson's disease: review of recent trials, Mov Disord, 28, 131, 10.1002/mds.25273 Honigfeld, 1998, Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry, J Clin Psychiatry, 59, 3 Burn, 2006, Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease, Mov Disord, 21, 1899, 10.1002/mds.21077 Cummings, 2014, Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial, Lancet, 383, 533, 10.1016/S0140-6736(13)62106-6 Seppi, 2011, The Movement Disorder Society evidence-based medicine review update: treatments for the non-motor symptoms of Parkinson's disease, Mov Disord, 26, S42, 10.1002/mds.23884 Richard, 2012, A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease, Neurology, 78, 1229, 10.1212/WNL.0b013e3182516244 Barone, 2010, Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial, Lancet Neurol, 9, 573, 10.1016/S1474-4422(10)70106-X Yarnall, 2011, The interplay of cholinergic function, attention, and falls in Parkinson's disease, Mov Disord, 26, 2496, 10.1002/mds.23932 Emre, 2004, Rivastigmine for dementia associated with Parkinson's disease, N Engl J Med, 351, 2509, 10.1056/NEJMoa041470 Chung, 2010, Effects of a central cholinesterase inhibitor on reducing falls in Parkinson disease, Neurology, 75, 1263, 10.1212/WNL.0b013e3181f6128c Henderson, 2013, The respond trial—rivastigmine to stabilise gait in Parkinson's disease a phase II, randomised, double blind, placebo controlled trial to evaluate the effect of rivastigmine on gait in patients with Parkinson's disease who have fallen, BMC Neurol, 13, 188, 10.1186/1471-2377-13-188 Kalia, 2013, Deep brain stimulation for Parkinson's disease and other movement disorders, Curr Opin Neurol, 26, 374, 10.1097/WCO.0b013e3283632d08 Fasano, 2012, Treatment of motor and non-motor features of Parkinson's disease with deep brain stimulation, Lancet Neurol, 11, 429, 10.1016/S1474-4422(12)70049-2 Schuepbach, 2013, Neurostimulation for Parkinson's disease with early motor complications, N Engl J Med, 368, 610, 10.1056/NEJMoa1205158